Analyst Recommendation Trends
Wall Street analyst consensus for AKBA over the last few months:
Latest AKBA News
SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to its Board of Directors
New director brings nephrology development expertise and over 30 years of experience in the biopharmaceutical industryJERSEY CITY, N.J., Sept. 22, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (“SCYNEXIS” or the “Company”), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today announced the appointment of Steven K. Burke, M.D., to its Board of Directors, effective September 18, 2026. Dr. Burke brings more than 30 years of indu
SCYNEXIS Appoints Todd Minga, M.D., as Senior Vice President, Research & Development
Experienced biopharmaceutical and nephrology leader joins SCYNEXIS to advance its rare disease development programsJERSEY CITY, N.J., Sept. 15, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (the Company or SCYNEXIS), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today announced the appointment of Todd Minga, M.D. as Senior Vice President, Research & Development, effective September 14, 2026. Dr. Minga brings more than two de
BTIG Reiterates Buy on Akebia Therapeutics, Maintains $4 Price Target
BTIG analyst Julian Harrison reiterates Akebia Therapeutics (NASDAQ:AKBA) with a Buy and maintains $4 price target.
Akebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney Diseases
Open-label Phase 2 trial evaluating ebribafusp for the treatment of IgA nephropathy, lupus nephritis and C3 glomerulopathy Initial data is expected in 2027 WALTHAM, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the first patient has been dosed in its Phase 2 basket trial evaluating ebribafusp for the treatment of rare complement-mediat
Akebia Therapeutics Doses First Patient In Phase 2 Basket Trial Of Ebribafusp In Rare Complement-Mediated Kidney Diseases
Open-label Phase 2 trial evaluating ebribafusp for the treatment of IgA nephropathy, lupus nephritis and C3 glomerulopathyInitial data is expected in 2027
WestPark Capital Initiates Coverage On Akebia Therapeutics with Buy Rating, Announces Price Target of $4.5
WestPark Capital analyst Ed Arce initiates coverage on Akebia Therapeutics (NASDAQ:AKBA) with a Buy rating and announces Price Target of $4.5.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-08-06 | Butler John P. | -350,000 | - | - |
| 2026-08-06 | Butler John P. | +350,000 | $0.63 | $220,500 |
| 2026-06-29 | Ostrowski Erik | -56,019 | $1.11 | $62,181 |
| 2026-06-17 | FRIESON RON | +53,600 | - | - |
| 2026-06-17 | FRIESON RON | +35,700 | - | - |
| 2026-06-17 | Wolf Myles | +53,600 | - | - |
| 2026-06-17 | Wolf Myles | +35,700 | - | - |
| 2026-06-17 | Smith Cynthia | +53,600 | - | - |
| 2026-06-17 | Smith Cynthia | +35,700 | - | - |
| 2026-06-17 | ADAMS ADRIAN | +53,600 | - | - |
| 2026-06-17 | ADAMS ADRIAN | +35,700 | - | - |
| 2026-06-17 | ROGERS MICHAEL W | +53,600 | - | - |
| 2026-06-17 | ROGERS MICHAEL W | +35,700 | - | - |
| 2026-06-17 | ZUMWALT LEANNE M | +53,600 | - | - |
| 2026-06-17 | ZUMWALT LEANNE M | +35,700 | - | - |
| 2026-04-01 | Vickers Philip J. | +214,400 | - | - |
| 2026-03-04 | Butler John P. | +69,270 | $1.25 | $86,588 |
| 2026-02-02 | Rucci Carolyn M. | -27,544 | $1.39 | $38,286 |
| 2026-02-02 | Rucci Carolyn M. | -25,382 | $1.39 | $35,281 |
| 2026-02-02 | Rucci Carolyn M. | -16,846 | $1.39 | $23,416 |
| 2026-02-02 | Malabre Richard C | -13,382 | $1.39 | $18,601 |
| 2026-02-02 | Malabre Richard C | -36,142 | $1.39 | $50,237 |
| 2026-02-02 | Ostrowski Erik | -34,951 | $1.39 | $48,582 |
| 2026-02-02 | Grund Nicholas | -31,244 | $1.39 | $43,429 |
| 2026-02-02 | Grund Nicholas | -53,585 | $1.39 | $74,483 |
| 2026-02-02 | Burke Steven Keith | -20,701 | $1.39 | $28,774 |
| 2026-02-02 | Burke Steven Keith | -25,375 | $1.39 | $35,271 |
| 2026-02-02 | Burke Steven Keith | -21,582 | $1.39 | $29,999 |
| 2026-02-02 | Butler John P. | -83,689 | $1.39 | $116,328 |
| 2026-02-02 | Butler John P. | +175,250 | $1.41 | $247,103 |
| 2026-02-02 | Butler John P. | -114,891 | $1.39 | $159,698 |
| 2026-02-02 | Butler John P. | -96,065 | $1.39 | $133,530 |
| 2026-02-02 | Butler John P. | -46,660 | $1.39 | $64,857 |
| 2026-01-30 | Rucci Carolyn M. | +270,000 | - | - |
| 2026-01-30 | Rucci Carolyn M. | +190,000 | - | - |
| 2026-01-30 | Malabre Richard C | +119,000 | - | - |
| 2026-01-30 | Malabre Richard C | +79,000 | - | - |
| 2026-01-30 | Ostrowski Erik | +320,000 | - | - |
| 2026-01-30 | Ostrowski Erik | +204,000 | - | - |
| 2026-01-30 | Grund Nicholas | +320,000 | - | - |
| 2026-01-30 | Grund Nicholas | +204,000 | - | - |
| 2026-01-30 | Burke Steven Keith | +320,000 | - | - |
| 2026-01-30 | Burke Steven Keith | +204,000 | - | - |
| 2026-01-30 | Butler John P. | +1,115,000 | - | - |
| 2026-01-30 | Butler John P. | +743,000 | - | - |